» Articles » PMID: 17472989

Autoantibodies Binding to Citrullinated Telopeptide of Type II Collagen and to Cyclic Citrullinated Peptides Predict Synergistically the Development of Seropositive Rheumatoid Arthritis

Overview
Journal Ann Rheum Dis
Specialty Rheumatology
Date 2007 May 3
PMID 17472989
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To find out whether autoantibodies to citrullinated telopeptides of type I and II collagens and to cyclic citrullinated peptides (CCPs) predict the development of rheumatoid arthritis (RA).

Methods: A case-control study (matched for sex, age and municipality) was nested within a Finnish cohort of 19072 adults who had neither arthritis nor a history of it at the baseline examination during 1973-7. 124 subjects developed RA by late 1989, and of these, 89 were positive for rheumatoid factor (RF). Preillness serum specimens were analysed for autoantibodies against arginine (A)- or citrulline (C)-containing synthetic telopeptides using a chemiluminescence method and for anti-CCPs Mark2 with an enzyme-linked immunosorbent assay method.

Results: The mean levels of autoantibodies to citrulline-containing telopeptides and the C/A ratios of type I and II collagens and to CCP were higher in subjects who later developed RF-positive RA. In the highest tertiles of C/A (I), C/A (II) ratios and anti-CCPs levels, the relative risk of RF-positive RA was significantly increased. In the multifactorial model, only anti-CCPs retained its statistical significance. However, the interaction term of C/A (II) ratio and anti-CCPs proved to be statistically significant (p = 0.02). The subjects ranked into the highest tertiles of both C/A (II) ratio and anti-CCPs had an odds ratio of 20.06 (95% confidence interval, 4.37 to 92.06) of developing RF-positive RA compared with those in the lowest tertiles of these antibodies. None of the autoantibodies predicted RF-negative RA.

Conclusion: Autoantibodies to citrullinated telopeptides of type I and II collagen and to CCPs exert a synergistic effect on the risk of seropositive RA.

Citing Articles

Engineered T cells and their therapeutic applications in autoimmune diseases.

Bao L, Bo X, Cao H, Qian C, Wang Z, Li B Zool Res. 2022; 43(2):150-165.

PMID: 35008131 PMC: 8920845. DOI: 10.24272/j.issn.2095-8137.2021.363.


Possible roles of anti-type II collagen antibody and innate immunity in the development and progression of diabetic retinopathy.

Ikeda T, Nakamura K, Kida T, Oku H Graefes Arch Clin Exp Ophthalmol. 2021; 260(2):387-403.

PMID: 34379187 PMC: 8786754. DOI: 10.1007/s00417-021-05342-6.


Cohort profile: SCREEN-RA: design, methods and perspectives of a Swiss cohort study of first-degree relatives of patients with rheumatoid arthritis.

Gilbert B, Lamacchia C, Mongin D, Lauper K, Trunk E, Studer O BMJ Open. 2021; 11(7):e048409.

PMID: 34261688 PMC: 8280908. DOI: 10.1136/bmjopen-2020-048409.


Separate and overlapping specificities in rheumatoid arthritis antibodies binding to citrulline- and homocitrulline-containing peptides related to type I and II collagen telopeptides.

Turunen S, Hannonen P, Koivula M, Risteli L, Risteli J Arthritis Res Ther. 2015; 17:2.

PMID: 25573503 PMC: 4320812. DOI: 10.1186/s13075-014-0515-z.


Reactive oxygen species deficiency induces autoimmunity with type 1 interferon signature.

Kelkka T, Kienhofer D, Hoffmann M, Linja M, Wing K, Sareila O Antioxid Redox Signal. 2014; 21(16):2231-45.

PMID: 24787605 PMC: 4224049. DOI: 10.1089/ars.2013.5828.


References
1.
Schellekens G, Visser H, de Jong B, van den Hoogen F, Hazes J, Breedveld F . The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000; 43(1):155-63. DOI: 10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3. View

2.
Aho K, Palosuo T, Heliovaara M, Knekt P, Alha P, von Essen R . Antifilaggrin antibodies within "normal" range predict rheumatoid arthritis in a linear fashion. J Rheumatol. 2000; 27(12):2743-6. View

3.
Risteli J, Koivula M, Risteli L . Citrullinated collagens in the pathogenesis of rheumatoid arthritis. Expert Rev Clin Immunol. 2010; 3(2):187-94. DOI: 10.1586/1744666X.3.2.187. View

4.
Reunanen A, Aromaa A, Pyorala K, PUNSAR S, Maatela J, Knekt P . The Social Insurance Institution's coronary heart disease study. Baseline data and 5-year mortality experience. Acta Med Scand Suppl. 1983; 673:1-120. View

5.
Couzin J . Clinical trials. Diabetes' brave new world. Science. 2003; 300(5627):1862-5. DOI: 10.1126/science.300.5627.1862. View